American Home Products Corporation

Janssen Pharmaceutica Nv

Wyeth

John A Moyer

Magid A Abou-Gharbia

John P Yardley

Wayne E Childers, Jr

Gary Paul Stack

Margaret Maria Zaleska

Michael Richard Brandt

Gahan J Pandina

Ryan Michael Wyatt

Bashkim Kadriu

Frank John Villani, Jr

Brian D Klein

Xun Li

Eric A Muth

G E Husbands

Michael Breslav

The disclosure relates to certain uses and methods of use of 3.1.0 and 4.1.0 azabicycle compounds of Formula (I), wherein X, Y, R, R, and Rare defined herein, and pharmaceutical compositions containing them, in the treatment of autism spectrum disorder, including Asperger's syndrome.

Monoacylglycerol lipase modulators for use in autism spectrum disorders

The present invention is directed to novel sulfamide derivatives, pharmaceutical compositions comprising said compounds and methods for the treatment of epilepsy and related disorders comprising administering to a subject in need thereof, said compounds, either alone or as co-therapy with one or more anticonvulsant and/or anti-epileptic agents.

Sulfamide derivative useful for the treatment of epilepsy

This invention provides a method of treating pain in a mammal that includes administering to a mammal in need of such treatment a pain treating effective amount of a compound of the formula (I): where Ris H, alkyl or phenylalkyl; Ris H, alkyl, alkenyl or phenylalkyl; or Rand Rtaken together as Z are &#x2014;CHC&#x2014;H&#x2014;, &#x2014;CHC(R)(R)CH&#x2014; or &#x2014;CHC(R)(R)&#x2014;C(R)(R)CH&#x2014;, where R, Rand Rare, independently, H, alkyl or hydroxyl and R, Rand Rare, independently, H or alkyl; A is alkylene or alkenylene; X is COR, P(O)(OR)(OR), 3,5-dioxo-1,2,4-oxadiazolidin-2-yl or 5-tetrazolyl in which R, Rand Rare, independently, H or alkyl, or a pharmaceutically acceptable salt thereof. The present invention also provides pharmaceutical compositions for treating pain containing a pain treating effective amount of the compound of formula (I).

[[2-(amino-3,4-dioxo-1-cyclobuten-1-yl)amino]alkyl]-acid derivatives for the treatment of pain

This invention provides a method of treating pain in a mammal that includes administering to a mammal in need of such treatment a pain treating effective amount of a compound of the formula (I): where Ris H, alkyl or phenylalkyl; Ris H, alkyl, alkenyl or phenylalkyl; or Rand Rtaken together as Z are &#x2014;CHCH&#x2014;, &#x2014;CH(CR)(R)CH&#x2014; or &#x2014;CHC(R)(R)&#x2014;C(R)(R)CH&#x2014;, where R, Rand Rare, independently, H, alkyl or hydroxyl and R, Rand Rare, independently, H or alkyl; A is alkylene or alkenylene; X is COR, P(O)(OR)(OR), 3,5-dioxo-1,2,4-oxadiazolidin-2-yl or 5-tetrazolyl in which R, Rand Rare, independently, H or alkyl, or a pharmaceutically acceptable salt thereof. The present invention also provides pharmaceutical compositions for treating pain containing a pain treating effective amount of the compound of formula (I).

[[2-(Amino-3,4-dioxo-1-cyclobuten-1-yl)amino]alkyl]-acid derivatives for the treatment of pain

This invention provides a method of inducing cognition enhancement in a mammal by administering to the mammal experiencing a cognition impairment an effective amount of a hydroxycycloalkanephenethyl amine compound of the following structural formula: ##STR1## in which A is a moiety of the formula ##STR2## wherein the dotted line represents optional unsaturation; R.sub.1 is hydrogen or alkyl; R.sub.2 is alkyl; R.sub.4 is hydrogen, alkyl, formyl, or alkanol; R.sub.5 and R.sub.6 are, independently, hydrogen, hydroxyl, alkyl, alkoxy, alkanoyloxy, cyano, nitro, alkylmercapto, amino, alkylamino, dialkylamino, alkanamido, halo, trifluoromethyl, or taken together, methylene dioxy; R.sub.7 is hydrogen or alkyl; and n is 0, 1, 2, 3, or 4; or a pharmaceutically acceptable salt thereof.

Venlafaxine in the inducement of cognition enhancement

There are disclosed the use of the compounds of the formula (I) ##STR1## wherein R.sup.1 is 1-adamantyl, 3-methyl-1-adamantyl, 3-noradamantyl, unsubstituted or substituted-2-indolyl, 3-indolyl, 2-benzofuranyl or 3-benzofuranyl wherein the substituents are selected from lower alkyl, lower alkoxy and halo; R.sup.2 is unsubstituted or substituted phenyl, benzyl, or pyrimidinyl wherein the substituents are selected from lower alkyl, lower alkoxy, trifluoromethyl and halo; R.sup.3 is H or lower alkyl of 1 to 3 carbon atoms; n is the integer 0 or 1; and m is the integer from 2 to 5 and the pharmaceutically acceptable salts thereof.

Use of aryl- and heteroaryl piperazinyl carboxamides in the treatment of

The invention relates to a method of treating alcoholism, sleep disorders or behavioral symptoms of Alzheimer's disease which comprises administration of bridged 2-(4-arylpiperazin-1-ylalkyl)-hexahydroisoindol-1,3-dione derivatives to a warm-blooded animal in need thereof.

Use of fused bicyclic imides in the treatment of various CNS disorders

A method for relieving depression with decahydro-3-[4-[4-(2-pyrimidinyl)-1-piperazinyl]butyl]-1,5-methano-6,7,9-m etheno-2H-pentaleno[1,2-d]azepine-2,4(3H)-dione, or a pharmaceutically acceptable salt thereof.

Antidepressant polycyclic imides to treat depression

N-(2-Methoxyphenyl)piperazine as a useful anxiolytic agent.

Anxiolytic activity of N-(2-methoxyphenyl)piperazine

There are disclosed compounds of the formula ##STR1## wherein X is O, S or NHR.sup.3, wherein R.sup.3 is hydrogen, lower alkyl or cycloalkyl;

Growing community of inventors

New Hope, PA, United States of America

John A Moyer